Horizon Pharma reported $244.43M in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Aerie Pharmaceuticals AERI:US $ -16.59M 15.45M
ALKERMES ALKS:US $ -15.07M 7.68M
Amgen AMGN:US $ 3004M 337M
AstraZeneca AZN:LN 3562M 625M
Bristol Myers Squibb BMY:US $ 5780M 8M
Cara Therapeutics CARA:US $ -27848000 5.61M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Endo International Ordinary Shares ENDP:US $ 226.56M 52.35M
Horizon Pharma HZNP:US $ 244.43M 47.12M
JAZZ PHA JAZZ:US $ 282.55M 15.29M
Novartis NOVN:VX SF 4660M 108M
Pacira Pharmaceuticals PCRX:US $ 34.04M 7.72M
Perrigo Ordinary Shares PRGO:US $ 92.6M 43.6M
Pfizer PFE:US $ 12921M 1739M
Prestige Brands PBH:US $ 95.4M 9.49M
Revance Therapeutics RVNC:US $ -56.84M 0.66M
Supernus Pharmaceuticals SUPN:US $ 31.99M 8.66M
Takeda 4502:JP Y 308798M 158143M
Teva Pharmaceutical Industries TEVA:US $ 1092M 20M
Valeant Pharmaceuticals VRX:CN $ 660M 156M
Xeris Pharmaceuticals Inc XERS:US $ -16042000 29.13M
Zoetis ZTS:US $ 854M 54M